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Introduction {#sec1}
============

Vascular development begins with the differentiation of endothelial cells (ECs) and the *de novo* formation of a primitive vascular network derived from angioblasts that first appear in the blood islands of the yolk sac and then migrate to the fetus where vascular networks are formed ([@bib21], [@bib33], [@bib58]). As development proceeds, this primitive network remodels, presumably triggered by changes in hemodynamics, surrounding cell types and environment, to establish a hierarchical vessel tree with tissue-specific functionality important for the function of each organ ([@bib2], [@bib14], [@bib28], [@bib40]). This development requires that ECs therefore deviate from an initial largely homogeneous embryonic population to acquire specific identities necessary to support the diverse needs of flow, transport, hormonal interactions, and cell trafficking across the endothelium of each organ ([@bib8], [@bib56]). Recent studies also showed that ECs may be derived from local progenitors in different organs or tissues, which further enhances the complexity and diversity in the response of ECs to injury and regenerative capacity ([@bib31], [@bib50], [@bib55], [@bib70], [@bib74]).

Although little is known about how each organ determines the functional properties of its endothelium, EC differences have been shown between arteries and veins, large and small vessels, and different microvascular beds in various organs ([@bib3], [@bib4], [@bib18], [@bib52]). Some of these properties depend on the tissue environment. Site-specific microenvironmental cues (i.e., cytokines, metabolites, biophysical signals, and direct cell-cell contact from parenchyma cells) communicate with ECs and induce posttranscriptional modification. In transplantation studies, ECs can be induced to gain other tissue-specific structural and morphologic phenotypes and gene expression patterns ([@bib5]).

EC properties are also under epigenetic control. Epigenetic footprints that control basal expression of endothelial-specific genes in different organs are specified early during embryonic development and preserved during sequential mitotic cycles ([@bib49]). When cells are removed from their *in vivo* microenvironment and grown in culture, most, but not all, gene expression patterns are lost upon passaging ([@bib13], [@bib38]). Nevertheless, a previous analysis of messenger RNA (mRNA) from several human EC lines revealed heterogeneous signatures even in passaged cells, providing evidence that epigenetic modification mediates differential gene expression profiles of ECs ([@bib18]).

A possible problem in the existing studies is that the ECs were isolated from different donors with various isolation methods for different tissues. Although this concern has been addressed in mouse species ([@bib45], [@bib52]), mouse ECs have different properties compared with human ECs and there are differences between human and mouse development ([@bib76]). These studies also failed to examine the cells as they formed vascular networks, a critical issue for organ-specific EC heterogeneity, or to show that gene expression data correlated with differences in cell functions. The *in vitro* stability is particularly important, in that the preservation of expression with passaging is needed for the study of mechanisms in human ECs and vascular development in the future.

In the present study, we address these challenges and investigate human EC heterogeneity via the following different categories: (1) basal protein expression in *ex vivo* microvascular tissue beds; (2) organ-specific EC population in tissue; (3) morphology, structure, protein expression, transcriptional profiling, and vascular function of ECs after isolation, culture, and passaging; and (4) transcriptional signature validation in freshly isolated ECs, for four major developing organs---the heart, kidney, liver, and lung---obtained from individual human fetal donors. Together, our findings provide a comprehensive heterogeneity reference library after multiple passages in stabilized culture for human organ-specific ECs at the cellular, molecular, and transcriptional levels. This study will also contribute to understanding organ-specific vascular development, injuries, and potential development of targeted therapeutic interventions.

Results {#sec2}
=======

Human Fetal ECs Show Organ-Specific Heterogeneity *Ex Vivo* {#sec2.1}
-----------------------------------------------------------

We examined the human fetal organ sets from three donors, constituting three biological replicates at 3 months\' gestation (100--125 days). At this stage, all four major organs of interest---the heart, kidney, lung, and liver---have an established microvascular supply and exhibit organ-specific function. The heart beats at 120--160 bpm and is approximately 2 cm, the lungs have developed the entire air-conducting bronchial tree up to 20 generations with respiratory ducts and start to form barriers between alveoli and blood vessels, the liver is the major site of blood cell production and has also started to produce bile, and the kidneys have established nephrons and start to produce urine.

The vasculature of each organ displayed a heterogeneous organization, identified by the expression of EC markers, such as CD31, a transmembrane glycoprotein that constitutes endothelial intercellular junctions; CD144 (vascular endothelial \[VE\] cadherin), a major endothelial adhesion molecule; and von Willebrand factor (vWF), a glycoprotein that mediates platelet adhesion in the endothelium ([Figure 1](#fig1){ref-type="fig"}A). In the heart, ECs formed an organized network and contained a large amount of Weibel-Palade bodies with high expression of vWF ([Figure 1](#fig1){ref-type="fig"}A, ii--v). In the lungs, although the expression of vWF was overall high and comparable to that of the heart ECs ([Figures 1](#fig1){ref-type="fig"}A and 1B), it varied in different regions. Lower vWF expression was associated with pulmonary capillary ECs located near small air-sac-like structures, whereas a vWF mosaic pattern appeared in ECs neighboring the bronchioles and larger airways ([Figures 1](#fig1){ref-type="fig"}A and 1C). In the liver, the ECs displayed low vWF expression in VECad+ cells ([Figures 1](#fig1){ref-type="fig"}A and 1B), whereas there are clustered non-ECs containing high granular VWF in the interstitium ([Figure 1](#fig1){ref-type="fig"}A v), indicating the presence of hematopoietic progenitors. In the kidneys, two distinct microvascular structures were identified, with higher vWF expression in glomerular ECs and lower expression in peritubular microvascular ECs ([Figures 1](#fig1){ref-type="fig"}A, 1B, and 1D).Figure 1Human Fetal Endothelial Cells Show Organ-Specific Heterogeneity *Ex Vivo*(A) (A) Representative immunofluorescence images of frozen tissue sections from fetal human kidney, lung, liver, and heart stained with antibodies against CD144 (i) and vWF (ii) with merged (iii) and zoomed (iv) views, and (v) CD31 and vWF. Scale bar: 50 μm (i--iii, v) and 25 μm (iv).(B--D) Quantification of vWF fluorescence area normalized to the number of CD31-positive cells for all four organs (B), within lungs (C), and kidneys (D). \*\*\*\* p ≤ 0.0001.(E) Representative immunofluorescence images of frozen tissue sections stained with antibodies against PV1 and Cav1. Scale bar: 50 μm.(F) Quantification of PV1 fluorescence area normalized to the number of CD31-positive cells for all four organs. \*\* p ≤ 0.01.(G) Representative flow cytometry profiles of fresh total cell tissue suspension from fetal human heart, lung, liver, and kidney stained with antibodies against CD45 and CD144. Endothelial population is gated as CD144-positive and CD45-negative cells (left panels). The percentage of endothelial cells is compared among tissues against the total cell number (right panel). Bar plots were made from n = 3 images per donor for two donors (B--D, F) or three donor sets (G). Data are presented as mean ± SEM \*p ≤ 0.05. SEM, standard error of the mean.

We then evaluated the structural differences of ECs in different fetal organs using the presence of caveolae, identified by the expression of caveolin-1 (Cav1), as well as stomatal and fenestral diaphragms, identified by the expression of plasmalemma vesicle-associated protein PLVAP (also called PV1)([@bib67], [@bib68], [@bib72]). Our study showed that the heart and lung microvasculature has nearly complete Cav1 and PV1 colocalization, suggesting that the presence of PV1 was confined to stomatal diaphragms---a signature of continuous endothelium ([Figures 1](#fig1){ref-type="fig"}E and 1F). On the other hand, the kidney microvasculature, in particular, presented higher levels of and more discrete PV1 outside of Cav1 colocalization, indicating the presence of fenestral diaphragms---a signature of fenestrated endothelium ([Figures 1](#fig1){ref-type="fig"}E and 1F).

Human Fetal ECs Present as Diverse Organ-Specific Populations {#sec2.2}
-------------------------------------------------------------

To characterize the EC population within different fetal organ microvascular beds and distinguish them from hematopoietic cells, we used the pan-hematopoietic marker CD45 in combination with CD144. ECs were identified as CD144 positive and CD45 negative (CD144^+^/CD45^-^) by flow cytometry. Single cell suspensions, obtained by enzymatic digestion of mechanically minced fresh tissue followed by the filtered removal of large vessels and tissue chunks, showed well-demarcated CD144^+^/CD45^-^ populations in each of the four fetal organs ([Figures 1](#fig1){ref-type="fig"}G and [S1](#mmc1){ref-type="supplementary-material"}A). The highest percentage of ECs was from the heart (mean ± standard error \[SE\]: 4.7% ± 0.7 %), whereas the lowest percentage of ECs was found in the liver (0.8% ± 0.3%); the kidney and lung ECs represented 3.4% ± 1.6% and 3.4% ± 0.7%, respectively, of the entire cell suspension. The liver was the only tissue that showed a significant CD144^+^/CD45^+^ double-positive population, supporting the hematopoietic role of this organ during early stages of development. Kidney and lung ECs show distinct CD144^+^ population from the epithelial cell population (Epcam^+^) with no overlap ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Among the CD144^+^/CD45^−^ cell population, the percentage for EphB4+ is 70%--90% for lung, liver, and kidney with no statistical significance among the three, whereas the heart cell suspension has significantly lower percentage for EphB4+ (∼25%). ([Figure S1](#mmc1){ref-type="supplementary-material"}C). The majority of these ECs are CD34+ (85%--90% for heart and kidney ECs) ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Less than 2% ECs are GP38+ (podoplanin) for all four vascular beds, suggesting little lymphatic vascular development at this stage ([Figure S1](#mmc1){ref-type="supplementary-material"}C). There is no detection of Robo1+ cells in this population (data not shown), which also suggests sufficient removal of large vessel tissue and minimal EC contaminations from large vessels ([Figure S1](#mmc1){ref-type="supplementary-material"}D).

Human Fetal ECs Retain *Ex Vivo* Heterogeneity upon *In Vitro* Expansion {#sec2.3}
------------------------------------------------------------------------

To study the persistence of EC heterogeneity *in vitro* and the epigenetic contribution to EC heterogeneity, we isolated and cultured the four human fetal organ-derived ECs through five passages (in each passage the cell number doubles). Important steps of the isolation procedure included the filtering and removal of large vessels and tissue chunks after enzymatic digestion, the removal of Epcam+ epithelial cell fraction from the whole tissue single cell suspension (particularly important for kidney and lung), the enrichment of the endothelial fraction through culture in low oxygen atmosphere with vascular endothelial growth factor (VEGF), the purification of the CD144+ endothelial fraction by flow cytometry, and the culture in VEGF-containing EC growth media for up to five passages (detailed in [Methods](#sec4){ref-type="sec"}). This isolation procedure also allows for the purification of other cell populations, important for further studies of regional organ heterogeneity and perivascular and parenchyma interactions ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). The majority of cultured ECs are EphB4+ (\>90%), with little contamination of lymphatic (GP38+ % \< 4%) or large vascular (Robo1+ % \< 1%) ECs; the CD34+ population in these cultured ECs ranges between 25% (liver) and 85% (kidney) ([Figure S2](#mmc1){ref-type="supplementary-material"}B).Figure 2Human Fetal ECs Retain the *Ex Vivo* Heterogeneity upon *In Vitro* Expansion(A) Representative flow cytometry and sorting profiles of enriched cell suspension from fetal human heart, lung, liver, and kidney, stained with antibodies against VECad, PDGFRb.(B and C) Representative immunofluorescence images of CD31 and vWF (B) and PV1 and Cav1 (C) fluorescence in cultured heart, lung, liver, and kidney ECs (scale bars: 50 μm).(D) Representative western blot analysis (i) and densitometric quantification (ii) of vWF, PV1, and caveolin expression on cell lysates obtained from four ECs, using GAPDH as the loading control (n = 3 donors). Data are presented as mean ± SEM \*\* p ≤ 0.01, \*\*\*\* p ≤ 0.0001. SEM, standard error of the mean.

Isolated ECs displayed typical endothelial cobblestone appearance and maintained their morphologies through five passages in culture ([Figure 2](#fig2){ref-type="fig"}B). ECs also expressed CD31 with a high purity, greater than 99%, for all four fetal organs ([Figure 2](#fig2){ref-type="fig"}B). Similar to the *ex vivo* expression patterns, the isolated heart and lung ECs contain higher levels of vWF proteins, whereas the kidney and liver ECs have more PV1 protein expression ([Figures 2](#fig2){ref-type="fig"}B--2D). PV1 distributed largely at the peripheral cell surface membrane of the kidney and to a lesser extent in the liver ECs, whereas only a small fraction colocalized with Cav1, indicating the presence and persistence of fenestral diaphragms in these two EC types after isolation and expansion. In contrast, the heart and lung ECs expressed much more Cav1 but less PV1 than the kidney and liver ECs, with PV1 located mostly in the perinuclear region in the heart and lung ECs.

We used these ECs at passage 2 to engineer three-dimensional endothelialized microvascular networks. These were embedded in collagen microfluidic channels and cultured under gravity-driven flow, as previously described ([@bib78]). Cells from all four sources created similar networks of tubular endothelium ([Figure 3](#fig3){ref-type="fig"}A). Ultrastructural analysis via transmission electron microscopy revealed the formation of junctional complexes at cell-cell contacts and distinctive structures along the cell periphery in four types of microvessels ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}). Engineered heart and lung microvessels showed focal contacts between adjacent cells and contained caveolae with stomatal diaphragms. Engineered kidney and liver microvessels showed complex and intercalated junctions between adjacent cells and presented numerous fenestrae (black arrows) along the peripheral regions of the cell membrane. The fenestrae in kidney endothelium contained diaphragms and had uniform morphology and size, whereas liver endothelium had discontinuous openings and contained fenestrae in varying sizes and structure along peripheral membranes. Not all fenestrae in the liver endothelium had diaphragms. In addition, the liver endothelium showed multivesicular bodies, lysosomes, and other distinct structures inside the cytoplasm ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}). Although not directly compared with the microvascular ultrastructure in the four fetal tissues, these results establish the structural heterogeneity of organ-specific structural endothelium *in vitro*, which is consistent with known organotypic vasculature *in vivo* ([@bib3], [@bib9]).Figure 3Ultrastructural Heterogeneity of Human Fetal ECs upon *In Vitro* Expansion(A) Projected immunofluorescence images and cross-sectional views of engineered perfusable, collagen-embedded, three-dimensional (3D) microvessel networks generated using the four types of organ-specific ECs (scale bar: 100 μm).(B) Transmission electron microscopy of 3D microvessel networks showing distinctive structural signatures. Black arrows indicate the presence of fenestrae, and red circles denote clathrin-coated alveolae.

Global RNA Sequencing Reveals Heterogeneous Gene Expression Profiles in Cultured Organ-Specific ECs {#sec2.4}
---------------------------------------------------------------------------------------------------

We next sought to determine whether these cells have distinct molecular signatures after removal from the original microenvironment. We collected RNA for transcript profiling using RNAseq from single-donor derived heart, lung, liver, and kidney ECs obtained from three different donors after two passages *in vitro*. A total of 102 transcription factors and 93 co-factors were identified as highly expressed (top 20% transcript intensities) in all four types of cultured ECs ([Figure S4](#mmc1){ref-type="supplementary-material"}A). These factors include known key regulators of vascular development such as ETS factor family (i.e., *ETS1*, *FLI1*, *ELK3*, *ELF1* etc), *ID* proteins, *KLF* gene family (i.e., *KLF3*, *KLF6*, *KLF10* etc), and genes important for vascular remodeling and VEGF signaling (i.e., *SP1*, *HES1*, *SOX18*, *HIF1A, NFKB1,* etc.) ([@bib24], [@bib43], [@bib53]).

Principle component analysis showed distinct clustering of heart-derived ECs compared with the other three EC types ([Figure 4](#fig4){ref-type="fig"}A), and Venn diagrams defined the characteristic gene clusters for heart-specific ECs ([Figure 4](#fig4){ref-type="fig"}B). Differential expression analysis and Gene Ontology terminology analysis ([Figures 4](#fig4){ref-type="fig"}C, [S4](#mmc1){ref-type="supplementary-material"}B, and S4C) showed that cultured heart ECs have higher gene expression levels, when compared with the other three types of ECs, with respect to extracellular matrix and structure organization, blood vessel morphogenesis, angiogenesis, VEGF production, heart chamber and valve morphogenesis, coronary vascular development and morphogenesis, branching morphogenesis, as well as regulation of vascular permeability. Compared with the heart ECs, lung ECs have higher expression for artery morphogenesis and development, developmental growth, and regionalization; liver ECs have higher expression for pattern specification, embryonic skeletal system development, regulation of leukocyte and homotypic cell-cell adhesion, regulation and activation of immune response, and bone marrow development; and kidney ECs in culture have higher expressions for regionalization, pattern specification process, embryonic organ morphogenesis/development/identity, hormone secretion and transport, and nephron development. These analyses are consistent with the corresponding stage of distinct organ development and function and indicate the important roles of different ECs in their corresponding organ development.Figure 4Global RNA Sequencing Reveals Heterogeneous Gene Expression Profiles among Four EC Types (n = 3 Donors)(A) 2D principle component analysis of RNA sequencing data for cultured organ-specific ECs showing clustered heart ECs compared with the kidney, lung, and liver ECs.(B) Venn diagram of differentially expressed heart-specific ECs genes with respect to kidney, lung, and liver ECs.(C and D) Gene Ontology terminology analysis (C) and volcano plot (D) showing different gene clusters for heart versus kidney ECs.(E) Heatmaps of bona fide markers for the heart-, kidney-, and lung-specific EC transcription factors and co-factors (i), angiocrine and signaling factors (ii), and metabolism-related and other genes (iii).(F) PCR validation of selected heart- and kidney-specific genes for additional three donor sets.

Differential expression analysis further revealed differentially expressed genes in paired comparison ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}D). For example, genes such as *GATA4*, *TBX5*, *TBX20*, and *HAND2* are expressed more than 200-fold higher in heart ECs, with high counts in RNAseq, compared with kidney ECs. These genes, although not studied in ECs, are known to be critical in heart development, heart valve formation, etc. ([@bib59], [@bib60]). Kidney ECs, on the other hand, highly and uniquely express many HOX genes that are known to be critical for kidney development. We further identified clustered genes as bona fide markers for organ-specific ECs by comparing one with the other three (fold change \> 1.5 and false discovery rate \[FDR\] \< 0.05). There are 74 heart-specific, 29 kidney-specific, 13 lung-specific highly expressed EC genes, whereas the numbers of liver-specific endothelial genes were not significant ([Figures 4](#fig4){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}E). These organ-specific genes include transcription factors and regulation co-factors, angiocrine factors, extracellular matrix proteins, cell adhesion molecules, membrane transporters, signaling molecules, and metabolism-related genes ([Figure 4](#fig4){ref-type="fig"}E).

Heart-derived ECs showed upregulated expression of zinc finger, T-box, and basic-helix-loop-helix transcription factors involved in heart and embryonic vascular development ([@bib12], [@bib29], [@bib60], [@bib61], [@bib75]) (*GATA6, HAND2, HEY2, TBX18*); transcription factors and co-factors involved in the heart valve and chamber development ([@bib15], [@bib19], [@bib44]) (*FHL1*); as well as factors involved in signaling regulation ([@bib11], [@bib16], [@bib32], [@bib57]) (*EBF3, NCOA7, PRRX1, RARB,* etc.). Kidney-derived ECs displayed upregulated expression of the helix-loop-helix transcription factor *EBF1*, which is critical in glomeruli development and maturation ([@bib30], [@bib62]), and the transcription factor *PAX2*, important for the regulation of branching morphogenesis and kidney development ([@bib51]). In addition, kidney ECs also expressed a large number of homeobox transcription factors, known as master developmental regulators in the kidney ([@bib41], [@bib54]) (*HOXA9, HOXB7, HOXB8, HOXB9, HOXC8, HOXC9, HOXD3, HOXD4, HOXD9, HOXD11*, etc.). Lung-derived ECs showed higher expression of the forkhead transcription factor *FOXF2,* known for the activation and regulation of pulmonary genes and embryonic development ([@bib6]); the T-box transcription factor *TBX4*, critical for lung branching ([@bib7]); and the co-factor *KHDRBS2,* which regulates signal transduction during lung development ([@bib46]). These organ-specific genes have not been found and studied in ECs previously, which may be important for the study of specific EC contribution during organ development.

Beside transcriptional regulators, heart-derived ECs highly expressed clusters of genes encoding for angiocrine factors, including annotated cytokines and growth factors (*CCL2, IL6, IL33*), signaling molecules, and extracellular matrix-remodeling proteins (*BMPER, C1QTNF1, CTSK, HAPLN1, IL6ST, LTBP1, PCOLCE2, PLAC9, POSTN, RGS5, SFRP4, TNFAIP8L3).* Other identified heart-derived EC-specific gene clusters included glycoproteins and surface receptors that mediate host defense, cell-cell adhesion and cell-matrix interaction (*COLEC12, EFEMP1, ITGB3, LRRC4B, FBLN1, RADIL, PCDH10, PRRT2, SELL, SRPX*), cytoplasm- and cytoskeleton-associated proteins (*AMPH, CLMN, DRP2, FRMD3, MYRIP, GRB14*), transporters (*KCNH7, GRB14, ABCA8, ABCA9, EVA1C, GPR158, NIPAL1, RASSF10, SLC7A2*), and metabolic regulators (*ART4, ATP13A3, CAMK2B, GCNT1, GLT8D2, PDE3A, PLA2G5, PLPP1, PTGS1, ST6GAL1,* etc.) ([Figure 4](#fig4){ref-type="fig"}F).

We validated the expression of selected genes from the kidney-specific and heart-specific EC gene lists by real-time polymerase chain reaction (PCR) analysis on both the RNA subjected to RNA sequencing and the three new RNA sets collected from single-donor organ-specific ECs ([Figure 4](#fig4){ref-type="fig"}F). The expression of EC genes identified as heart specific (i.e., *HAND2*, *TBX18*, *IL33*, *ART4, ABCA8, BMPER, RGS5, TNFAIP8L3, HAPLN1,* and *SMAD7*) were significantly upregulated in the heart-derived ECs compared with the kidney-derived ECs, and conversely kidney-specific genes (i.e., *PAX2, HOXC10, MMP7,* and *HNF1B*) were significantly upregulated in kidney-derived ECs. These organ-specific genes have minimal changes in the expression level through passage 5 ([Figure S4](#mmc1){ref-type="supplementary-material"}F). We further used quantitative PCR (qPCR) analysis to validate the low expression of perivascular cell genes (i.e., NG2 and PDGFRb), confirming the absence of contaminating perivascular cells ([Figure S4](#mmc1){ref-type="supplementary-material"}G).

Altogether, gene expression data show that ECs from fetal organs maintain organ-specific transcription profiles; in particular, heart-derived ECs display distinct clusters of transcription factors, angiocrine factors, surface glycoproteins, and metabolism that significantly distinguish these ECs from the other three EC types.

*In Vitro-Ex Vivo* Correlation of EC Heterogeneity {#sec2.5}
--------------------------------------------------

We then examined the EC heterogeneity *ex vivo* via RNAseq analysis and *in situ* immunofluorescence microscopy, to validate organ-specific gene clusters identified from cultured cells and further differentiate between the environmental and epigenetic contributions to EC heterogeneity. Freshly isolated ECs were collected via column purification with Epcam^−^CD144^+^/CD45^−^, and high-quality RNA were extracted for sequencing to assess gene expression in three single-donor organ sets. Column purification significantly enhanced cell survival during fresh isolation process. Fluorescence-activated cell sorting analysis for the column-purified ECs showed 70%--98% CD144+ cells and with no detectable perivascular cell contaminations for all four organs ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Principal component analysis revealed that ECs isolated from the four organs were distinct from each other, with organ replicates clustering tightly together ([Figure S5](#mmc1){ref-type="supplementary-material"}B), suggesting higher degree of organ specificity when compared with the *in vitro* cultured ECs. Comparing heart and kidney ECs alone, there were more than 5,000 genes differentially expressed with significance in freshly isolated ECs, whereas only 867 genes were identified in culture (fold change \>1.5 and FDR \<0.1). This suggests that the majority of differentially expressed genes were likely dependent on the native microenvironment. However, a small portion of the expressed RNAs remained differentially expressed even in culture, suggesting that the differentiation has occurred at an epigenetic level. A potential epigenetic assay would help to confirm the epigenetic stability of ECs between *in vivo* and *in vitro* cultures.

Most top transcription factors and co-factors commonly expressed in culture were also highly expressed in freshly isolated ECs, whereas genes such as *KLF2*, *KLF4*, *SOX4, SOX7, ID2*, *SNAI1*, *NR4A1*, and *EGR3*, were significantly downregulated after *in vitro* expansion ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D). Among these highly expressed genes in freshly isolated sets, 32 transcription factors and 17 co-factors were differentially expressed in at least one type of EC and five transcription factors (*ETS1, ELK3, SOX18, HMGA1, SOX7*) were highly expressed with significant variation among all the ECs ([Figure S5](#mmc1){ref-type="supplementary-material"}C), a difference not detected in cultured EC sets. Other top transcription factors, such as *COUP-TFII (NR2F2)* and *ETS2,* were differentially expressed in kidney versus heart, whereas *ERF, ID1, E2F4,* and *SOX4* in the liver are different from those in the kidney, heart, and lung, which appear similar. These transcription factors have been recognized as important regulators of EC development and specification, and their differential expression suggests that vascular development occurs at a different pace in some of the four organs at the gestation time evaluated.

Next we validated the differentially expressed genes from cultured cells in freshly isolated cell sets, using heart and kidney paired comparison. Although the majority of differentially expressed genes in EC sets *in vivo* were lost after culture, over 100 highly upregulated genes (fold change \>10) in either the heart or kidney ECs identified in culture remained elevated in freshly isolated ECs ([Figure 5](#fig5){ref-type="fig"}A). These differentially expressed gene clusters represent the epigenetic contribution to the organ-specific EC signature, which has the capacity to maintain in culture. Some of these identified genes were also verified in immunofluorescence staining in *ex vivo* tissues ([Figure 5](#fig5){ref-type="fig"}B: human and [Figure 5](#fig5){ref-type="fig"}C: mouse). The loss of differential expression of the highly expressed genes, from freshly isolated ECs to the cultured ECs, suggested the significant microenvironmental specifications for the developing ECs.Figure 5Validation of Heterogeneous Gene Expression Profiles in Freshly Isolated ECs and *Ex Vivo* Tissue Sections (n = 3 Donors)(A) Organ-specific genes identified from cultured sets (heart versus kidney) were validated in freshly isolated EC sets.(B) Immunostaining of selected genes for heart and kidney in human fetal tissues at 120 days. Scale bar: 100 μm.(C) Selected organ-specific gene expression in mouse embryo for heart and kidneys at E14.5 from Genepaint ([genepaint.org](http://genepaint.org){#intref0015}).

Heart-Derived ECs Have the Highest Transendothelial Electrical Resistance, Angiogenic Potential, and Metabolic Rates among All Four ECs {#sec2.6}
---------------------------------------------------------------------------------------------------------------------------------------

We next evaluated whether the variations in the transcriptional profiles of the four different EC types in culture led to distinct functions with respect to their barrier properties, angiogenic potential, and metabolic rates *in vitro*. To match the cell condition (passage 2) in RNAseq analysis, we used four ECs from single donor sets at the same passage number and culture media conditions for all the functional studies. Using xCELLigence RTCA SP instrumentation (ACEA Bioscience), we measured the real-time electrical impedance of EC monolayers at a particular frequency (*f =* 10 kHz). When EC monolayer reached confluency, the electrical impedance, recorded as the cell index, reached a plateau ([Figure 6](#fig6){ref-type="fig"}A), from which the transendothelial electrical resistance was measured. The monolayer of heart-derived ECs showed the highest electrical resistance (∼35 ± 1 Ω at *f =* 10 kHz) with statistical significance, whereas the electrical resistance of the kidney-derived ECs was the lowest among the four ECs (∼ 21 ± 2 Ω) ([Figure 6](#fig6){ref-type="fig"}A), supporting a better barrier function for the heart ECs when compared with cultured ECs from the fetal kidney.Figure 6Cultured Organ-Specific Human Fetal ECs Display Distinct Vascular Functions and Bioenergetics and Support Specific Parenchyma Function(A) Left panel: Raw data of transendothelial electrical resistance measurement versus time for four types of ECs in monolayer culture. Cell index is calculated as $CI\left( t \right) = \frac{R\left( {f_{n},t} \right) - R\left( {f_{n},t_{0}} \right)}{Z_{n}}$, where f~n~ is the frequency at which the impedance measurement is carried out (*f*~*n*~ = 10 kHz), *R(f*~*n,*~*t)* is the measured impedance at frequency *f*~*n*~ at time point *t*, *t*~*0*~ is the time when the background is measured, and *Z*~*n*~ is the corresponding frequency factor of *f*~*n*~ (*Z*~*n*~ = 15 Ω). Right panel: Electrical impedance measurements (10 kHz frequency) for confluent monolayers of organ-specific ECs (n = 5 cultures).(B) Spheroid sprouting assay measurements of organ-specific EC angiogenic potential. (i) Representative bright-field images of heart and kidney EC sprouting spheroids, collagen-embedded, upon 24 hr of VEGF stimulation (40 ng/mL) (scale bar: 75 μm) and (ii) quantification of sprouts number at baseline and after VEGF stimulation (40 ng/mL) for organ-specific EC spheroids embedded in collagen matrix (24 hr) (n = 3 donors).(C) Seahorse measurements of total cellular oxygen consumption rate (OCR) in organ-specific ECs: (i) time course of cellular oxygen consumption upon sequential addition of oligomycin (1 μM), CCCP (1 μM), and rotenone/antimycin A (1 μM each); (ii) quantification of mitochondrial OCR obtained upon electron transport chain inhibition with rotenone and antimycin A; and (iii) quantification of mitochondrial OCR due to ATP synthase activation obtained upon ATP synthase inhibition with oligomycin (n = 3 donors).(D) Seahorse measurements of total extracellular acidification rate (ECAR) in organ-specific ECs (n = 3 donors): (i) time course of extracellular acidification upon sequential addition of oligomycin (1 μM), CCCP (1 μM), and rotenone/antimycin A (1 μM each) and (ii) ECAR quantification.(E) ELISA measurement of albumin production from rat hepatocytes when cultured alone and when co-cultured with heart, lung, liver, and kidney ECs after 7 days (n = 4 replicates).Data information: data are presented as mean ± SEM \*p ≤ 0.05, \*\*p ≤ 0.01, \*\*\*p ≤ 0.001, \*\*\*\*p ≤ 0.0001. SEM, standard error of the mean.

We then evaluated the ability of the ECs derived from four fetal organs to form new vessels *in vitro* using the spheroid sprouting assay ([@bib34]). Endospheroids were embedded in collagen and methylcellulose matrix and overlaid with endothelial growth medium, with or without 40 ng/mL VEGF, and grown for 24--48 hr to allow sprout formation ([Figure 6](#fig6){ref-type="fig"}B, i). Without VEGF exposure, most endospheroids were quiescent and devoid of any sprouting, except for the heart endospheroids. In the presence of 40 ng/mL VEGF, all endospheroids showed angiogenic activity, which was evident from the extensive capillary-like sprout formations. However, under VEGF exposure, heart endospheroids displayed a significantly higher number of sprouts ([Figure 6](#fig6){ref-type="fig"}B, ii).

Finally, we examined EC metabolism through the measurements of cellular oxygen consumption (respiration) and proton excretion (glycolysis) with a Seahorse Analyzer ([Figures 6](#fig6){ref-type="fig"}C and 6D). The oxygen consumption rate and extracellular acidification rate were measured at baseline, and in the presence of oligomycin, CCCP (carbonyl cyanide m-chlorophenylhydrazone), and rotenone/antimycin A, which were added sequentially ([Figure 6](#fig6){ref-type="fig"}C), and allowed for the calculation of respiration rates due to mitochondrial activity, ATP synthase, and spare capacities, as well as the glycolysis rate. Heart ECs showed the highest oxygen consumption rate due to an increase in both non-mitochondrial and mitochondrial respiration, which relied on enhanced ATP synthase activity, and also a significant spare respiratory capacity. A significantly higher glycolysis rate in addition to the mitochondrial respiration ([Figure 6](#fig6){ref-type="fig"}D) demonstrated that heart ECs possess the highest metabolic rate among the four types of ECs investigated, consistent with enhanced energetic support that can fuel a higher angiogenic potential.

Human Fetal Liver ECs Support Hepatocyte Function {#sec2.7}
-------------------------------------------------

We further examined whether organ-specific ECs can support specific parenchyma function. The four types of human fetal ECs at passage 2 were co-cultured with primary hepatocytes freshly isolated from rat liver. Each type of ECs was added on top of primary rat hepatocyte monolayers after their attachment for 24 hr following fresh isolation, at a ratio of 1 endo: 3 hepatocytes. Rat albumin was measured via enzyme-linked immunosorbent assay (ELISA) in media collected every 24 hr and compared after 7 days of culture. Co-culturing with ECs showed significant improvement in general compared with hepatocytes culture alone, in both albumin production and hepatocyte survival ([Figures 6](#fig6){ref-type="fig"}E and [S6](#mmc1){ref-type="supplementary-material"}). Hepatocytes co-cultured with liver ECs showed significantly higher albumin production (∼200 μg/million cells per day) than those co-cultured with heart, lung, and kidney ECs ([Figure 6](#fig6){ref-type="fig"}E). Liver ECs appeared to provide additional signaling that promotes hepatocyte function ([Figure S6](#mmc1){ref-type="supplementary-material"}C).

Discussion {#sec3}
==========

Twenty years ago, studies in chick quail hybrids showed that the endothelium all over the body arises from blood islands that first appear in the embryonic yolk sac ([@bib26], [@bib42]). Cells that arise from these early structures migrate throughout the body forming branches, and with time, they organize themselves into the arborized network of the adult arteries, veins, and capillaries. The initial formation of blood islands and tubes is called "vasculogenesis." The lymphatic system develops in a similar fashion, originating from the venous branches. Blood vessels themselves can develop branches, primarily from the postcapillary venules. These branches form the vasculature of organs. More recently, it appears that endothelia can also arise locally within the mesenchyme of organs, including the heart and lungs. Thus diversity might arise both by interaction with parenchyma and by changes within the branched structure itself. Obviously, determining mechanisms that control local differentiation of ECs is difficult in whole tissue. We felt, therefore, that it would be desirable to develop cell lines. Because cells from fetuses usually have long replicative life spans, we chose to derive EC lines from four fetal tissues. We show that these human fetal ECs maintain stable organ-specific morphology and gene expression through five passages in culture. These fetal ECs express genes that are supportive to specific organ development and are different in metabolism, gene expression, and angiogenic responses to VEGF that may be relevant *in vivo*.

Among many possible organ-specific endothelial properties, we focused on three major categories: (1) vessel barrier, (2) angiogenic potential, and (3) metabolic functions. From a structural point of view, we showed that heart and lung ECs are continuous endothelium with focal close-contact junctions and no fenestrae formation, whereas kidney and liver ECs contain abundant fenestrae along the peripheral cell membrane but have complex intercalated junctions. These transcellular fenestrae would allow for large molecules to transport directly across the kidney and liver endothelium with low resistance, coinciding therefore with lower barrier strength. In addition, heart ECs have higher expression levels for adherent junctions, which not only contribute to higher barrier but also play important roles in signaling ([@bib10]). Heart ECs also showed significantly higher transendothelial electrical resistance than kidney and liver ECs. Although not achieving physiological level of barrier in a monolayer culture ([@bib36]), these data suggest that at least one route of transport (transcellular or paracellular) ([@bib37], [@bib48]) is higher in kidney and liver ECs compared with the heart ECs.

Our study specifically addressed ECs from the heart, liver, kidney, and lung, mainly owing to the tissue availability, and did not investigate ECs from other organs, such as the highly permeable high endothelial venules or the impermeable brain vasculature with unique distribution of tight junctions ([@bib35], [@bib63]). Future studies of these ECs could provide more insights into the heterogeneous structure and molecular regulation of the endothelial barrier.

The second organ-specific property we demonstrated was the different angiogenic potential of ECs. Interestingly, heart ECs proved much more angiogenic than the other ECs derived from the other three organs under the same culture conditions and in the presence of identical stimuli. The higher angiogenic function in heart ECs is supported by a distinct cluster of genes categorized as angiocrine factors and signaling factors. These genes not only regulate angiogenesis but also provide important paracrine signaling for the maturation and function of developing cardiomyocytes. The different angiogenic potential may also be due to the specific origin of each EC type. Heart ECs are derived from at least three different sources, including the endocardium, sinus venous, and proepicardium ([@bib77]). Recent studies showed that ECs may even originate from different germ layers ([@bib25], [@bib31], [@bib50], [@bib66], [@bib74]). These varied origins could then lead to different capacities for angiogenesis via differential epigenetic control.

The endothelium has been shown critical to organ development and maturation, for example, in the pancreas, liver, and kidney ([@bib1], [@bib17], [@bib20], [@bib39], [@bib62], [@bib71], [@bib73]), and can serve as progenitors for perivascular cells ([@bib17]). It is possible that the endothelium is required to facilitate the differentiation of endoderm or mesoderm in the heart and to achieve mature function. Here, organ-specific EC identities, defined from the developing organs, could provide instructional signals toward the construction of organ-specific vascular microenvironments, and further the maturation of the developing parenchyma. This regulatory feedback system involving the endothelium is likely critical for successful organ regeneration, and for engineering functional parenchyma *in vitro* using stem cells.

We also observed heterogeneity in organ-specific EC metabolism. Remarkably, heart ECs showed the highest rates of oxygen consumption and glycolysis, supported by a distinct cluster of upregulated genes involved in metabolic regulation. ECs in mature vessel beds, despite their exposure to high oxygen levels, are known to be quiescent and to rely mostly on glycolysis ([@bib27]). During activation, ECs increase mitochondrial activity ([@bib47]), as well as glycolysis for energy production ([@bib22], [@bib23]). However, little is known as to whether endothelial mitochondrial ATP generation is static or varies between vascular beds. Little is also known about the role of endothelial metabolism during development. Metabolism has been recently noted to be critical in regulating stem cell fate during early differentiation ([@bib64], [@bib65], [@bib69]). Our findings suggest that metabolism may also play an important role during the differentiation of endothelium toward organ-specific vasculature.

We further demonstrated the supportive role of these human fetal ECs in organ development and function by co-culturing with hepatocytes. Interestingly, these fetal ECs support hepatocyte survival and function, and liver-specific ECs also showed significantly superior supportive function in terms of albumin production from the hepatocytes. Although the mechanisms remain elusive and require investigation in depth, this functional study showed proof of principle that organ-specific ECs would be beneficial to support organ development, and engineer organ-on-a-chip to better recapitulate structure and function *in vivo*.

In summary, we have examined transcription profiles from fetal ECs cultured and passaged from four major human organs--- the heart, lung, liver, and kidneys. We showed the distinct structural, and functional properties maintained over at least five passages in these four types of ECs. The results are still preliminary in several ways. First, we do not know how many more passages these cell lines can go through while preserving these properties. Longer replicative life spans could provide us with cells that would be reproducible reagents for mechanistic studies. Second, we do not know how closely the cultured cells themselves have diverse expression patterns that could represent the diversity of different EC phenotypes *in vivo*. For example, the high incidence in EphB4-positive cells in cultured sets suggest that endothelium form veins may be over-represented. Significant loss of differentially expressed genes from *in vivo* after culture suggest the importance of identifying environmental cues *in vivo* to understand and recapitulate the vascular and organ function. Third, although we did see some diversity in the structures of the EC-cell junctions, our measurement of electrical resistance suggests that none of these cell lines reproduce the functional impermeability of ECs with tight junctions. This is a general issue with cultured ECs with, as far as we know, only two reported exceptions. Aside from the cell junction, this may be important for other EC functions including control of endothelial differentiation by VE cadherin and shear-dependent transcription dependent on several cell junction proteins.

Nevertheless, our findings allowed us to identify for the first time the linkage between human EC heterogeneity and organ development, and differentiation between the intrinsic and microenvironment contribution to human EC heterogeneity. The availability of methods to culture organ-specific ECs makes it feasible to understand several organ-specific processes, including heart valve formation through the studies of endothelial-mesenchymal transition *in vitro*, formation and functional maturation of the kidney filtration barrier, and gas exchange interface in the lungs. Our work also provides important insights toward identifying precise organ-specific vascular targets and developing appropriate therapeutic interventions toward the treatment of organ-related vascular injuries and diseases.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================

Document S1. Transparent Methods and Figures S1--S6
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